An open label, balanced, randomized, two-treatment, four-period, two-sequence, single-dose, crossover fully replicate bioequivalence study comparing Mesalamine delayed release capsules 400 mg manufactured by Sun Pharmaceutical Industries Limited, India with Mesalamine Delayed-Release Capsules 400 mg, manufactured for Teva Pharmaceuticals USA, Inc. Parsippany, NJ 07054, in healthy, adult, human subjects under fasting condition.

2025-520617-31-00 Protocol MESAL-19-24 Human pharmacology (Phase I) - Bioequivalence study Ongoing, recruitment ended

Start 12 Sep 2025 · Status Ongoing, recruitment ended · 1 EU/EEA countries · 1 sites · Protocol MESAL-19-24

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Bioequivalence study
Status Ongoing, recruitment ended
Participants planned 112
Countries 1
Sites 1

ulcerative colitis

Key facts

Sponsor
Sun Pharmaceutical Industries Limited
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Diseases [C] - Digestive System Diseases [C06]
Trial duration
12 Sep 2025 → ongoing
Decision date (initial)
2025-06-25
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

ulcerative colitis

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Sun Pharmaceutical Industries Limited

Sponsor organisation
Sun Pharmaceutical Industries Limited
Address
1 Plot No 201 B, Western Express Highway, Goregaon East Western Express Highway Goregaon East
City
Mumbai
Postcode
400063
Country
India

Scientific contact point

Organisation
Sun Pharmaceutical Industries Limited
Contact name
Arshad Khuroo

Public contact point

Organisation
Sun Pharmaceutical Industries Limited
Contact name
Arshad Khuroo

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Romania Ongoing, recruitment ended 112 1
Rest of world 0

Investigational sites

Romania

1 site · Ongoing, recruitment ended
Terapia S.A.
Clinical Pharmacology and Pharmacokinetics, Strada Fabricii Nr. 124, 400640, Cluj-Napoca

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Romania 2025-09-12 2025-09-15 2025-10-01

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2025-02-28 Romania No conclusion
2025-06-17
2025-06-25